DE60215315D1 - Verwendung von fusionsproteinen, deren n-terminaler teil aus einem hirudinderivat besteht, zur herstellung rekombinanter proteine durch sekretion durch hefen - Google Patents

Verwendung von fusionsproteinen, deren n-terminaler teil aus einem hirudinderivat besteht, zur herstellung rekombinanter proteine durch sekretion durch hefen

Info

Publication number
DE60215315D1
DE60215315D1 DE60215315T DE60215315T DE60215315D1 DE 60215315 D1 DE60215315 D1 DE 60215315D1 DE 60215315 T DE60215315 T DE 60215315T DE 60215315 T DE60215315 T DE 60215315T DE 60215315 D1 DE60215315 D1 DE 60215315D1
Authority
DE
Germany
Prior art keywords
nucleic acid
acid sequence
hirudin
proteins
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60215315T
Other languages
English (en)
Other versions
DE60215315T2 (de
Inventor
Paul Habermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Priority to DE60215315T priority Critical patent/DE60215315T2/de
Application granted granted Critical
Publication of DE60215315D1 publication Critical patent/DE60215315D1/de
Publication of DE60215315T2 publication Critical patent/DE60215315T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60215315T 2001-02-20 2002-02-08 Verwendung von fusionsproteinen, deren n-terminaler teil aus einem hirudinderivat besteht, zur herstellung rekombinanter proteine durch sekretion durch hefen Expired - Lifetime DE60215315T2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE60215315T DE60215315T2 (de) 2001-02-20 2002-02-08 Verwendung von fusionsproteinen, deren n-terminaler teil aus einem hirudinderivat besteht, zur herstellung rekombinanter proteine durch sekretion durch hefen

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10108211 2001-02-20
DE10108211A DE10108211A1 (de) 2001-02-20 2001-02-20 Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen
PCT/EP2002/001308 WO2002070722A1 (en) 2001-02-20 2002-02-08 Use of fusion proteins whose n-terminal part is a hirudin derivative for the production of recombinant proteins via secretion by yeasts
DE60215315T DE60215315T2 (de) 2001-02-20 2002-02-08 Verwendung von fusionsproteinen, deren n-terminaler teil aus einem hirudinderivat besteht, zur herstellung rekombinanter proteine durch sekretion durch hefen

Publications (2)

Publication Number Publication Date
DE60215315D1 true DE60215315D1 (de) 2006-11-23
DE60215315T2 DE60215315T2 (de) 2007-05-24

Family

ID=7674912

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10108211A Withdrawn DE10108211A1 (de) 2001-02-20 2001-02-20 Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen
DE60215315T Expired - Lifetime DE60215315T2 (de) 2001-02-20 2002-02-08 Verwendung von fusionsproteinen, deren n-terminaler teil aus einem hirudinderivat besteht, zur herstellung rekombinanter proteine durch sekretion durch hefen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE10108211A Withdrawn DE10108211A1 (de) 2001-02-20 2001-02-20 Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen

Country Status (22)

Country Link
US (1) US20030176673A1 (de)
EP (1) EP1364032B1 (de)
JP (1) JP4199543B2 (de)
KR (1) KR100858833B1 (de)
CN (1) CN1279171C (de)
AT (1) ATE342367T1 (de)
AU (1) AU2002250903B2 (de)
BR (1) BR0207379A (de)
CA (1) CA2439042C (de)
CY (1) CY1106274T1 (de)
DE (2) DE10108211A1 (de)
DK (1) DK1364032T3 (de)
ES (1) ES2272696T3 (de)
HK (1) HK1065068A1 (de)
IL (2) IL157416A0 (de)
MX (1) MXPA03007116A (de)
NO (1) NO331376B1 (de)
NZ (1) NZ527642A (de)
PE (1) PE20020857A1 (de)
PT (1) PT1364032E (de)
WO (1) WO2002070722A1 (de)
ZA (1) ZA200305868B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638618B2 (en) * 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
DE102006031955A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
RU2524423C2 (ru) 2008-01-09 2014-07-27 Санофи-Авентис Дойчланд Гмбх Новые производные инсулина с чрезвычайно замедленным профилем время/действие
DE102008025007A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
WO2009087082A2 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
KR101972301B1 (ko) 2009-11-13 2019-04-25 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ－１ 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물
BR112012011403B8 (pt) 2009-11-13 2021-05-25 Sanofi Aventis Deutschland composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma
CA2809321C (en) 2010-08-30 2018-08-14 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
HUE027989T2 (en) 2011-08-29 2016-11-28 Sanofi Aventis Deutschland A pharmaceutical composition for use in glycemic control in patients with type 2 diabetes
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
SI3229828T1 (sl) 2014-12-12 2023-06-30 Sanofi-Aventis Deutschland Gmbh Formulacija s fiksnim razmerjem inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0158564B1 (de) * 1984-03-27 1992-07-15 Transgene S.A. Expressionsvektoren für Hirudin, transformierte Zellen und Verfahren zur Herstellung von Hirudin
US5705355A (en) * 1984-03-27 1998-01-06 Transgene, S.A. Hirudin, pharmaceutical compositions comprising it and their use
DE3738541A1 (de) * 1987-11-13 1989-05-24 Hoechst Ag Verfahren zur isolierung und reinigung von hirudin
US6875589B1 (en) * 1988-06-23 2005-04-05 Hoechst Aktiengesellschaft Mini-proinsulin, its preparation and use
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
DE4009268A1 (de) * 1990-03-22 1991-09-26 Consortium Elektrochem Ind Sekretion von hirudinderivaten
DK0511393T3 (da) * 1990-11-08 1996-12-09 Japan Energy Corp Hirudin-mutant, fremstilling af denne, antikoagulant, sekretorisk vektor, mikroorganisme transformeret af vektoren og fremstilling af produkt ud fra mikroorganismen
FI92601C (fi) * 1992-03-11 1994-12-12 Marja Makarow Menetelmä hyötyproteiinien erittämiseksi hiivoista
DE19543737A1 (de) * 1995-11-24 1997-05-28 Hoechst Ag Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices
DE19544233A1 (de) * 1995-11-28 1997-06-05 Hoechst Ag Verfahren zur Nutzung des Hefe-ADH II-Promotorsystems zur biotechnologischen Produktion heterologer Proteine in hohen Ausbeuten
DK0889949T3 (da) * 1996-03-13 2003-09-22 Delta Biotechnology Ltd Fermenteringskontrol
DE10033195A1 (de) * 2000-07-07 2002-03-21 Aventis Pharma Gmbh Bifunktionale Fusionsproteine aus Hirudin und TAP
US7202059B2 (en) * 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium

Also Published As

Publication number Publication date
US20030176673A1 (en) 2003-09-18
PE20020857A1 (es) 2002-11-04
DE10108211A1 (de) 2002-08-22
BR0207379A (pt) 2004-06-15
CA2439042C (en) 2013-06-18
EP1364032A1 (de) 2003-11-26
IL157416A0 (en) 2004-03-28
IL157416A (en) 2009-08-03
EP1364032B1 (de) 2006-10-11
NZ527642A (en) 2005-03-24
CN1279171C (zh) 2006-10-11
ZA200305868B (en) 2005-02-23
KR100858833B1 (ko) 2008-09-17
KR20030074841A (ko) 2003-09-19
MXPA03007116A (es) 2003-11-18
CA2439042A1 (en) 2002-09-12
JP4199543B2 (ja) 2008-12-17
CY1106274T1 (el) 2011-10-12
DE60215315T2 (de) 2007-05-24
ATE342367T1 (de) 2006-11-15
WO2002070722A1 (en) 2002-09-12
PT1364032E (pt) 2007-01-31
AU2002250903B2 (en) 2006-12-07
DK1364032T3 (da) 2007-02-19
ES2272696T3 (es) 2007-05-01
CN1526021A (zh) 2004-09-01
NO20033672D0 (no) 2003-08-19
NO331376B1 (no) 2011-12-12
NO20033672L (no) 2003-10-17
HK1065068A1 (en) 2005-02-08
JP2004518446A (ja) 2004-06-24

Similar Documents

Publication Publication Date Title
DE60215315D1 (de) Verwendung von fusionsproteinen, deren n-terminaler teil aus einem hirudinderivat besteht, zur herstellung rekombinanter proteine durch sekretion durch hefen
Vedvick et al. High-level secretion of biologically active aprotinin from the yeast Pichia pastoris
Lind et al. Novel forms of B‐domain‐deleted recombinant factor VIII molecules: construction and biochemical characterization
Johansson et al. Surfactant protein B: disulfide bridges, structural properties and kringle similarities
KR100227167B1 (ko) 인체혈청알부민의 n-말단 단편을 함유하는 융합단백질
EP0322094B1 (de) N-terminale Fragmente von menschlichem Serumalbumin
AU619553B2 (en) Aprotinin analogues and a process for the production thereof
Bratt et al. Cleavage of the α1-microglobulin-bikunin precursor is localized to the Golgi apparatus of rat liver cells
KR870005098A (ko) 융합 단백질의 제조방법
DK105489D0 (da) Polypeptid
CY1105696T1 (el) Υπερεκκρινομενα πεπτιδια, διεργασιες για την παραγωγη τους και παραλληλη βελτιωση του εκκρινομενου ειδους ενος ή περισσοτερων αλλων πεπτιδιων
Qian et al. Isolation and characterization of sheep lactoferrin, an inhibitor of platelet aggregation and comparison with human lactoferrin
WO1995029686A1 (en) Recombinant fibrin chains, fibrin and fibrin-homologs
WO2006062398A3 (en) Methods for the production and secretion of modified peptides
Arlaud et al. Complete amino acid sequence of the catalytic chain of human complement subcomponent C. hivin. 1r
Yamada et al. Separation of recombinant human interleukin-2 and methionyl interleukin-2 produced in Escherichiacoli
DK0755447T3 (da) Rekombinante proteiner af filamentøst hæmagglutinin fra Bordetella, især Bordetella Pertussis, fremgangsmåde til fremstilling heraf samt anvendelse heraf i fremstillingen af fremmede proteiner eller vacciner
JPS646219A (en) Peptide having promoting action on activation of protein c by thrombin
ATE527364T1 (de) Polypeptide erhaltend eine modifizierte menschliche serum-albumin sekretions-pre-sequenz mit erhöhtem ausscheidungsertrag
Ronne et al. 7S Nerve growth factor. alpha. and. gamma. subunits are closely related proteins
Degryse et al. Addition of a dipeptide spacer significantly improves secretion of ovine trophoblast interferon in yeast
Olins et al. Phosphorylation of high‐and low‐molecular‐mass atrial natriuretic peptide analogs by cyclic AMP‐dependent protein kinase
Przysiecki et al. Characterization of recombinant antistasin secreted by Saccharomyces cerevisiae
Chow et al. Expression of recombinant human glucose-dependent insulinotropic polypeptide in Escherichia coli by sequence-specific proteolysis of a protein A fusion protein
Asakura et al. The enhancement of the extracellular carboxyl-terminal domain of human growth hormone receptor on growth hormone dependent responses of 3T3-F442A cells

Legal Events

Date Code Title Description
8364 No opposition during term of opposition